# Cardinal Health, Inc. (CAH): Investor Outlook on Strong Analyst Buy Ratings with 20.62% Potential Upside

- Link: https://www.directorstalkinterviews.com/cardinal-health-inc-cah-investor-outlook-on-strong-analyst-buy-ratings-with-20-62-potential-upside/4121212434
- Published: 2025-08-18T10:16:54+01:00
- Author: Madison Wilson

Cardinal Health, Inc. (NYSE: CAH) stands as a formidable player in the healthcare
sector, specifically within the medical distribution industry. With a substantial
market capitalization of $35.73 billion, Cardinal Health operates on a global scale,
offering a diverse range of healthcare services and products. This includes pharmaceutical
distribution, specialty solutions, and a comprehensive suite of medical products
and services tailored to meet the needs of healthcare providers and patients alike.

Currently trading at $149.61, Cardinal Health’s stock has seen a price change of-
0.61, remaining stable with no percentage change on the day. The 52-week range highlights
a low of $107.89 and a peak at $168.00, showcasing significant volatility and growth
potential within this period. Analysts have set a target price range between $150.00
and $203.00, with an average target price of $180.46, suggesting a potential upside
of 20.62%.

Valuation metrics reveal a forward P/E of 14.09, a figure that investors may find
reasonable given the company’s stable revenue growth and robust market position.
While other valuation metrics such as the PEG ratio, price/book, and price/sales
are not available, the forward P/E indicates expectations of steady earnings growth.

Performance metrics show a modest revenue growth rate of 0.50%, with an earnings
per share (EPS) of 6.45. The company’s free cash flow stands strong at approximately
$2.07 billion, providing a solid foundation for future investments, debt reduction,
or shareholder returns. The dividend yield is a modest 1.37%, with a payout ratio
of 31.43%, indicating a sustainable dividend policy that balances rewarding shareholders
and retaining capital for growth.

Cardinal Health enjoys favorable sentiment among analysts, with 11 buy ratings and
5 hold ratings, while notably absent are any sell ratings. This overwhelming confidence
reflects the company’s resilient business model and strategic position in the healthcare
supply chain. The technical indicators present a mixed picture: the stock’s 50-day
moving average of $159.23 suggests a recent dip below this short-term trend, while
the 200-day moving average of $137.07 indicates a longer-term upward trend. The 
relative strength index (RSI) at 61.95 shows the stock is nearing overbought territory,
hinting at potential price corrections, while the MACD and signal line indicate 
a bearish momentum.

Founded in 1979 and headquartered in Dublin, Ohio, Cardinal Health has built a legacy
of innovation and service excellence. Its operations span pharmaceutical and specialty
solutions, global medical products, and distribution, addressing the needs of hospitals,
pharmacies, and healthcare providers worldwide. The company’s comprehensive offerings,
from medical and surgical products to pharmacy management services, position it 
as a critical player in the healthcare ecosystem.

For investors, Cardinal Health presents a compelling case for consideration. The
stock’s potential upside of over 20% based on analyst targets, coupled with a robust
cash flow and strategic market positioning, offer attractive prospects. As the healthcare
industry continues to evolve, Cardinal Health’s adaptability and comprehensive service
offerings could provide sustained growth opportunities for investors looking to 
capitalize on the sector’s potential.

Share on: